Compliance with results reporting at ClinicalTrials.gov

New England Journal of Medicine

Volumn 372, Issue 11, 2015, Pages 1031-1039

  Anderson, Monique L ^a,b   Chiswell, Karen ^b   Peterson, Eric D ^a,b   Tasneem, Asba ^b   Topping, James ^b   Califf, Robert M ^a,c  

^a Division of Cardiology   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CLINICAL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; FUNDING; HEALTH SERVICES RESEARCH; INSTITUTIONALIZATION; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FACTUAL DATABASE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HUMAN; INTERPERSONAL COMMUNICATION; LEGISLATION AND JURISPRUDENCE; LIBRARY; MANDATORY PROGRAM; PROPORTIONAL HAZARDS MODEL; REGISTER; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION;

ALGORITHMS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISCLOSURE; DRUG INDUSTRY; GOVERNMENT REGULATION; HUMANS; MANDATORY PROGRAMS; NATIONAL LIBRARY OF MEDICINE (U.S.); PROPORTIONAL HAZARDS MODELS; REGISTRIES; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84924691950     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsa1409364     Document Type: Article

References (25)

1. Kesselheim AS, Mello MM. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Health Aff (Millwood) 2007;26:483-91.
2. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
4. Food and Drug Administration Amendments Act of 2007. (Public Law No. 110-85 § 801; 2007.)
5. ClinicalTrials.gov. FDAAA 801 requirements (http://clinicaltrials.gov/ct2/manage-recs/fdaaa).
6. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database - update and key issues. N Engl J Med 2011;364:852-60.
7. Gill CJ. How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the Clinicaltrials.gov database. BMJ Open 2012;2(4):e001186.
8. Law MR, Kawasumi Y, Morgan SG. Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. Health Aff (Millwood) 2011;30:2338-45.
9. Nguyen TA, Dechartres A, Belgherbi S, Ravaud P. Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol 2013;31:2998-3003.
10. Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012;344:d7373.
11. Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain? A statistical analysis of the ClinicalTrials.gov database. PLoS One 2014;9(7):e101826.
12. Kuehn BM. Few studies reporting results at US government clinical trials site. JAMA 2012;307:651-3.
13. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000;283:2701-11.
14. Drazen JM, Morrissey S, Curfman GD. Open clinical trials. N Engl J Med 2007;357:1756-7.
15. Clinical Trials Transformation Initiative. AACT database (http://ctti-clinicaltrials.org/what-we-do/analysis-dissemination/state-clinical-trials/aact-database).
16. Tasneem A, Aberle L, Ananth H, et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS One 2012;7(3):e33677.
17. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012;307:1838-47.
18. Shalowitz DI, Miller FG. Disclosing individual results of clinical research: implications of respect for participants. JAMA 2005;294:737-40.
19. Pfizer.com. Clinical case study series: disclosure of clinical trials information, 2009 (https://www.pfizer.com/files/research/research-clinical-trials/Disclosure-ClinicalTrialsInformation-030209.pdf).
20. GSK.com. Global public policy issues: public disclosure of clinical research, April 2014 (http://www.gsk.com/media/280827/disclosure-of-clinical-trial-information-policy.pdf).
21. Merck.com. Public policy statement: clinical trials data disclosure, July 2014 (http://www.merck.com/about/views-and-positions/Clinical%20Trials%20Data%20Disclosure%20-%20July%202014.pdf).
22. Feczko J. Clinical trials report card. N Engl J Med 2006;354:1426-9.
23. Department of Health and Human Services. U. S. Food and Drug Administration response letter to the Honorable Leonard Lance, July 10, 2014 (http://nebula.wsimg.com/402766aac55d29eb46728087 828d33de?AccessKeyId=B353B9F4C0E2B8 32754F&disposition=0&alloworigin=1).
24. Federal Register. Clinical trials registration and results submission: a proposed rule by the National Institutes of Health on 02/13/2015 (https://www.federalregister.gov/articles/2015/02/13/2015-02990/clinical-trials-registration-and-results-submission).
25. Laine C, Horton R, De Angelis CD, et al. Clinical trial registration - looking back and moving ahead. N Engl J Med 2007;356:2734-6.